Bristol-Myers Squibb (BMY)

Don't overthink it. These are blue chip stocks that have simply gone on sale and would be solid additions to almost any income portfolio.

Bristol-Myers Squibb's iza-bren cut breast cancer progression risk by up to 38% in a Phase 3 trial, lifting shares and raising implications for rivals like Exelixis.

The healthcare stock trades at a forward earnings multiple of just nine, and its growth rate has been in the low single digits this year.

These stocks pay yields far above the S&P 500's. And they keep raising their dividends.

SystImmune, Inc. (SystImmune), a clinical stage biotechnology company, and Bristol Myers Squibb (NYSE: BMY) today announced that SystImmune’s parent company Sichuan Biokin Pharmaceutical, Ltd. (Biokin) reported positive results from a prespecified interim analysis in the randomized, multicenter Phase 3 PANKU-Lung01 (NCT06382116) study evaluating izalontamab brengitecan (iza-bren), an investigational, first-in-class, dual-targeting EGFRxHER3 bispecific antibody-drug conjugate (ADC), versus platinum-based chemotherapy (PBC) in patients with EGFR-mutated non-squamous non-small cell lung cancer (NSCLC) who were previously treated with an EGFR tyrosine kinase inhibitor (TKI). Results will be presented today in a late-breaking oral presentation at the European Society for Medical Oncology (ESMO) 2026 Annual Congress taking place October 23 – 27 in Madrid, Spain, and simultaneously published in The Lancet.

Bristol Myers Squibb is facing a sizable patent cliff, but that's not unusual in the pharma sector.

Bristol Myers Squibb (NYSE: BMY) today announced disclosure of interim safety and efficacy results from the multiple sclerosis (MS) cohorts of the Phase 1, single-arm, dose-escalation Breakfree-2 study evaluating zolacabtagene autoleucel (zola-cel; BMS-986353), an investigational, autologous CD19-directed CAR T cell therapy, in patients with highly active relapsing MS (haRMS) and progressive forms of MS (PMS). The data are being presented today in an oral presentation (Abstract #1615) at MSToronto 2026, the 10th Joint ACTRIMS-ECTRIMS Meeting taking place in Toronto, Canada.

Pathos AI, a clinical-stage AI and technology company advancing its own therapeutic pipeline, today announced multi-year strategic collaborations with Bristol Myers Squibb (NYSE: BMY, “BMS”) and Tempus AI, Inc. (NASDAQ: TEM, “Tempus”) to build a specialized, curated dataset and agentic AI capabilities for Alzheimer’s disease and other neurological conditions. BMS also leads Pathos’s Series E financing and gains access to Pathos Foundry across its broader R&D portfolio.

SystImmune, Inc. (SystImmune), a clinical-stage biotechnology company, and Bristol Myers Squibb (NYSE: BMY) today announced that SystImmune’s parent company Sichuan Biokin Pharmaceutical, Ltd. (Biokin) reported positive results from a prespecified interim analysis of the randomized Phase 3 PANKU-Breast01 study (NCT06343948) evaluating izalontamab brengitecan (iza-bren), an investigational, potentially first-in-class, dual-targeting EGFRxHER3 bispecific antibody-drug conjugate (ADC), versus chemotherapy in patients with unresectable locally advanced, recurrent or metastatic hormone receptor-positive (HR+)/HER2-negative (HER2-) breast cancer who have failed at least one prior line of chemotherapy. Results will be presented today in a late-breaking oral presentation at the European Society for Medical Oncology (ESMO) 2026 Annual Congress taking place October 23–27 in Madrid, Spain, and simultaneously published in The Lancet.

One of these pharma stocks offers more income, but the other offers a safer dividend.

Pfizer's revenue swung sharply lower before stabilizing, while Bristol Myers Squibb kept climbing steadily—a divergence that matters for long-term investors.

Bristol Myers Squibb has led in seven of eight quarters, but Novo Nordisk's recent spike signals a shift worth watching for income-focused investors.

Eli Lilly's revenue nearly doubled over two years while Bristol Myers Squibb remained relatively flat, widening the gap between these two pharma giants.

AbbVie's revenue lead has widened to $4 billion per quarter, but Bristol Myers shows surprising resilience despite slower growth.

Amgen boasts stronger revenue growth, while Bristol Myers Squibb generates nearly 60% more free cash flow at half the valuation.

Consider this pharma company's turnaround, not its dividend, its main appeal.

Wall Street’s bearish price targets for the stocks in this article signal serious concerns. Such forecasts are uncommon in an industry where maintaining cord...

Bristol Myers Squibb (NYSE: BMY) today announced it will present new data from its oncology portfolio and pipeline across a broad range of solid tumors at the European Society for Medical Oncology (ESMO) 2026 Congress to be held October 23-27 in Madrid, Spain. Across 12 oral presentations and nearly 60 disclosures, the company will highlight progress across differentiated therapeutic approaches, including:

It has been a volatile year for the biotech.

Bristol-Myers trades at a significant valuation discount, but its higher leverage and patent risks contrast sharply with Johnson & Johnson's diversified stability.